Colorectal Cancer: Zaltrap Efficacy for BRAF and RAS Mutations
Colorectal Cancer: Zaltrap Efficacy for BRAF and RAS Mutations
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
Colorectal Cancer: Zaltrap Efficacy for BRAF and RAS Mutations
- August 21, 2017
- Reading time: 1 minute
This article discusses WCG 2017 findings regarding Aflibercept (brand name: Zaltrap, known as Soft Cancer Arrest Injection in Taiwan), a second-line therapy for colorectal cancer. This drug shows higher efficacy in patients with BRAF gene mutations or RAS wild-type gene mutations.
Presented by Dr. Sabine Tejpar from University Hospital Leuven, Belgium, at the ESMO 19th Gastrointestinal Cancer Conference (WCGC2017) held June 28-July 1 in Barcelona, Spain. This analysis examined tumor markers and assessed DNA/RNA from patient samples across 591 participants.
For KRAS gene exon2 wild-type analysis (281 patients), the median overall survival (OS) was 11.6 months (95% CI: 10.5-15.9) in the placebo group and 14.9 months (95% CI: 12.4-18.0) in the Zaltrap group.
For KRAS gene exon2 mutation (201 patients), median OS was 10.6 months (95% CI: 8.1-14.0) in the placebo group and 12.6 months (95% CI: 10.2-14.5) in the Zaltrap group.
For RAS wild-type analysis (218 patients), median OS was 11.7 months (95% CI: 10.1-15.9) in the placebo group and 16.0 months (95% CI: 12.7-22.8) in the Zaltrap group.
For BRAF wild-type analysis (446 patients), median OS was 12.4 months (95% CI: 10.7-15.1) in the placebo group and 13.0 months (95% CI: 12.4-15.9) in the Zaltrap group.
For BRAF gene mutation (36 patients), median OS was 5.5 months (95% CI: 3.5-10.6) in the placebo group and 10.3 months (95% CI: 5.3-NA) in the Zaltrap group.
According to Dr. Tejpar, for advanced colorectal cancer with BRAF mutations receiving second-line therapy, the median OS of 10.3 months in the Zaltrap group exceeds that observed with EGFR antibody medications.
#Colorectal Cancer
-
Clinical Trial Drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Show Promising Results in Phase II Trial. (Lung Cancer) HER2 Gene Mutation Non-Small Cell Lung Cancer: Is Enhertu Effective? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4